Blue Cross Blue Shield of Michigan is engaged in the most consequential reimbursement negotiations with hospitals in its 86-year history. The Detroit insurer, the state’s most dominant with a 63% ...

Eli Lilly just dropped $1 billion—plus a $300 million bonus if trials go well—on gene therapy firm Verve, aiming to spice up ...

B Verve Therapeutics (VERV) acquisition offers investors a 70%+ premium. See why I think this deal is beneficial to both ...

Discover the latest business news including rising gas prices, Zepbound shipments, At Home bankruptcy, and the Federal Reserve meeting.

Under Lilly’s savings-card program for commercially insured people who lack coverage for Zepbound, a one-month prescription for Zepbound pens now costs a minimum of $650, up from $550 previously.

Zepbound is a glucagon-like peptide-1 (GLP-1) agonist drug with the active ingredient tirzepatide. It comes as a weekly injectable prescription weight loss medication that has two main functions ...

Eli Lilly is claiming another victory in a head-to-head trial comparing its weight-loss drug Zepbound to its main rival Wegovy from Novo Nordisk. The full data from the 751-subject SURMOUNT-5 ...

we'll continue to implement new options that improve the affordability and availability of our safe, approved, and studied Zepbound for patients who are being asked to pay out-of-pocket," he added.

Forbes contributors publish independent expert analyses and insights. I’m an ER doc, public health researcher and patient advocate.